399 related articles for article (PubMed ID: 33843449)
1. Developments and opportunities in continuous biopharmaceutical manufacturing.
Khanal O; Lenhoff AM
MAbs; 2021; 13(1):1903664. PubMed ID: 33843449
[TBL] [Abstract][Full Text] [Related]
2. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
3. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.
Konstantinov KB; Cooney CL
J Pharm Sci; 2015 Mar; 104(3):813-20. PubMed ID: 25417595
[TBL] [Abstract][Full Text] [Related]
4. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
5. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
6. Potential of Continuous Manufacturing for Liposomal Drug Products.
Worsham RD; Thomas V; Farid SS
Biotechnol J; 2019 Feb; 14(2):e1700740. PubMed ID: 29781114
[TBL] [Abstract][Full Text] [Related]
7. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
8. Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales.
Hummel J; Pagkaliwangan M; Gjoka X; Davidovits T; Stock R; Ransohoff T; Gantier R; Schofield M
Biotechnol J; 2019 Feb; 14(2):e1700665. PubMed ID: 29341493
[TBL] [Abstract][Full Text] [Related]
9. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
Fisher AC; Kamga MH; Agarabi C; Brorson K; Lee SL; Yoon S
Trends Biotechnol; 2019 Mar; 37(3):253-267. PubMed ID: 30241924
[TBL] [Abstract][Full Text] [Related]
10. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility.
Garcia FA; Gefroh E
Drug Discov Today; 2023 Jul; 28(7):103619. PubMed ID: 37201779
[TBL] [Abstract][Full Text] [Related]
11. Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?
Rathore AS; Thakur G; Kateja N
Biotechnol Bioeng; 2023 Feb; 120(2):333-351. PubMed ID: 36111450
[TBL] [Abstract][Full Text] [Related]
12. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
13. White paper on high-throughput process development for integrated continuous biomanufacturing.
São Pedro MN; Silva TC; Patil R; Ottens M
Biotechnol Bioeng; 2021 Sep; 118(9):3275-3286. PubMed ID: 33749840
[TBL] [Abstract][Full Text] [Related]
14. Industrialization of mAb production technology: the bioprocessing industry at a crossroads.
Kelley B
MAbs; 2009; 1(5):443-52. PubMed ID: 20065641
[TBL] [Abstract][Full Text] [Related]
15. Decline in economic returns from new drugs raises questions about sustaining innovations.
Berndt ER; Nass D; Kleinrock M; Aitken M
Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
[TBL] [Abstract][Full Text] [Related]
16. Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing.
Crowley L; Cashen P; Noverraz M; Lobedann M; Nestola P
Biotechnol Bioeng; 2024 Mar; 121(3):877-893. PubMed ID: 38214109
[TBL] [Abstract][Full Text] [Related]
17. Continuous downstream processing of biopharmaceuticals.
Jungbauer A
Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674
[TBL] [Abstract][Full Text] [Related]
18. Mammalian cell culture capacity for biopharmaceutical manufacturing.
Ecker DM; Ransohoff TC
Adv Biochem Eng Biotechnol; 2014; 139():185-225. PubMed ID: 23748352
[TBL] [Abstract][Full Text] [Related]
19. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
